Related Experiment Video

Updated: May 25, 2025

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise
05:06

Author Spotlight: Integrating Tai Chi with Mindfulness Training to Achieve an Effective Mind-Body Exercise

Published on: July 14, 2023

1.6K

Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with

Sára Csiha1,2,3, Marcell Hernyák3,4, Ágnes Molnár4

  • 1Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.

Biomedicines
|February 26, 2025
PubMed

Insights

Alpha-lipoic acid (ALA) therapy reduced advanced glycation end products (AGEs) in type 2 diabetes patients. This reduction may improve endothelial function and diabetic neuropathy.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Vascular Biology

Background:

  • Type 2 diabetes mellitus (T2DM) is linked to macro- and microvascular complications.
  • Advanced glycation end products (AGEs) contribute to vascular and nerve tissue damage in T2DM.
  • Investigating the impact of alpha-lipoic acid (ALA) on AGEs and endothelial dysfunction is crucial.

Purpose of the Study:

  • To evaluate the effect of ALA on AGEs, soluble AGE receptor (sRAGE), and the AGE/sRAGE ratio in T2DM patients.
  • To assess the correlation between ALA treatment, endothelial dysfunction parameters, and neuropathy.
  • To determine if ALA influences AGEs and related biomarkers.

Main Methods:

  • A 6-month intervention study involving 54 T2DM patients with neuropathy receiving daily oral ALA (600 mg).
  • A control group of 24 T2DM patients without neuropathy.
  • Measurements included AGEs, sRAGE, AGE/sRAGE ratio, and endothelial dysfunction markers.

Main Results:

  • Alpha-lipoic acid therapy significantly reduced AGEs levels in T2DM patients (p = 0.017).
  • ALA treatment did not affect sRAGE levels or the AGEs/sRAGE ratio.
  • Changes in AGEs correlated with improvements in nerve function (current perception threshold) and progranulin levels.

Conclusions:

  • ALA treatment effectively decreases AGEs in T2DM patients.
  • Reduced AGEs by ALA may contribute to its known benefits in diabetic neuropathy.
  • ALA shows potential for improving endothelial function in T2DM.
Keywords:
ADMAAGEsadvanced glycation end productsalpha lipoic acidatherosclerosisdiabetic neuropathyoxidative stressprogranulinsRAGE

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

113
A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

3.5K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
227
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
142
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
152
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
162
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291